Abstract: Thermal monitoring and analysis of conditions in a power electronic system include sensing of thermal parameters of interest, such as temperature and humidity in an enclosure housing power electronic components. The components are cooled by a liquid coolant flow from a chiller through chiller plates associated with the power electronic components. Air is circulated through the enclosure for heat rejection from the chiller plates. Based on the sensed parameters, factors such as relative humidity and dew point of the cooling air may be computed and evaluated to determine the potential for condensation. Alarms, notices, or recommendations may be output for regulation of the chiller to avoid condensation. The system may also provide for evaluation of installation errors, and degradation of performance over time.

Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.

Abstract: Described herein are solid forms of N-(4-fluoro-5-(((2S,4R)-4-46-methoxypyrimidin-4-yl)oxy)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide, compound (I): (I) and the process of making said solid forms of compound (I). The present invention further relates to a pharmaceutical composition comprising crystalline Form A and Form B of compound (I), and methods of using said form and pharmaceutical composition in the treatment and prevention of Alzheimer's disease and related neurological disorders.

Abstract: Thermal monitoring and analysis of conditions in a power electronic system include sensing of thermal parameters of interest, such as temperature and humidity in an enclosure housing power electronic components. The components are cooled by a liquid coolant flow from a chiller through chiller plates associated with the power electronic components. Air is circulated through the enclosure for heat rejection from the chiller plates. Based on the sensed parameters, factors such as relative humidity and dew point of the cooling air may be computed and evaluated to determine the potential for condensation. Alarms, notices, or recommendations may be output for regulation of the chiller to avoid condensation. The system may also provide for evaluation of installation errors, and degradation of performance over time.

Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).

Abstract: Methods and formulations for minimizing or avoiding the sorption of glyburide to surfaces of delivery tubing, filters, bags, and other containers and materials, thereby storing and delivering a more stable product, delivering a predictable and accurate dose of glyburide, while minimizing impurities, avoiding drug waste, reducing cost, and significantly reducing the amount of dosing solution that must be infused into the patient.

Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).

Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[2-fluorophenyl)methyl]oxy}phenyl-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.

Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.

Abstract: A microgrid according to an exemplary aspect of the present disclosure includes, among other things, a plurality of intelligent electronic devices configured to communicate directly with one another in a first language. Each of the intelligent electronic devices includes a controller and a gateway. The gateway is configured to convert incoming messages from the first language to a second language native to the controller. The first language is different than the second language. A method is also disclosed.

Abstract: A microgrid controller includes a database in communication with a processor. The processor is operable to receive at least one microgrid input, to determine a first plurality of optimal power characteristic levels at a corresponding one of a plurality of first time intervals for a first time period, and to determine a second plurality of optimal power characteristic levels of a device determined at a corresponding one of a plurality of second time intervals for a second time period. The first time intervals are found at a first frequency different than a second frequency of the second time intervals. One of the second plurality of optimal power characteristic level corresponds to one of the first plurality of optimal power characteristic levels at each first time interval. The processor is configured to control a device optimal power characteristic level in response to the second plurality of optimal power characteristic levels.

Abstract: A system for providing route recommendations for field service technicians is provided. The system includes a processor for performing operations that include identifying a current geographic location of a service technician and receiving a list of tasks for the service technician. A plurality of route options are generated for the service technician based at least in part on the list of tasks and the current geographic location of the service technician. Each of the plurality of route options includes a geographic location of at least one of the tasks in the list of tasks. The route options are output.

Abstract: Provided are a smart shoe, a smart device and a method for switching functional area. The smart shoe includes a shoe body and a smart device provided on a surface of the shoe body. The smart device includes a processing unit, a locating unit, a communication unit, a solar energy receiving unit and a power supply unit. The locating unit is configured to acquire current position information of the smart shoe and send it to the processing unit. The processing unit sends the received position information to a user terminal or a remote server via the communication unit. The solar energy receiving unit is configured to receive solar energy and converting it into electrical energy which is transferred to the power supply unit. The power supply unit is connected with individual functional units of the smart device to supply the electrical energy to the smart device.

Abstract: A system and method for debris particle detection with adaptive learning are provided. The method includes receiving oil debris monitoring (ODM) sensor data from an oil debris monitor sensor and fleet data from a database, detecting a feature in the ODM sensor data, generating an anomaly detection signal based on detecting an anomaly by comparing the feature in the ODM sensor data to a limit defined by system information stored in the fleet data, selecting a maintenance action request based on the anomaly detection signal, and adjusting one or more of the feature, the anomaly, the limit, and the maintenance action request by applying an adaptive learning algorithm that uses the ODM sensor data, fleet data, and feedback from field maintenance of one or more engines that evolves over time.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.